The Qiagen Therascreen® PIK3CA RGQ PCR Kit for the detection of 11 mutations in the PIK3CA gene in ctDNA and/or tumor tissue received U.S. regulatory approval for use in guiding treatment decisions in patients with breast cancer undergoing treatment with Alpelisib [28]. This evidence concerns the gene PIK3CA and breast cancer.